Nature Communications (Aug 2023)

Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity

  • Daniel M. Altmann,
  • Catherine J. Reynolds,
  • George Joy,
  • Ashley D. Otter,
  • Joseph M. Gibbons,
  • Corinna Pade,
  • Leo Swadling,
  • Mala K. Maini,
  • Tim Brooks,
  • Amanda Semper,
  • Áine McKnight,
  • Mahdad Noursadeghi,
  • Charlotte Manisty,
  • Thomas A. Treibel,
  • James C. Moon,
  • COVIDsortium investigators,
  • Rosemary J. Boyton

DOI
https://doi.org/10.1038/s41467-023-40460-1
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Among the unknowns in decoding the pathogenesis of SARS-CoV-2 persistent symptoms in Long Covid is whether there is a contributory role of abnormal immunity during acute infection. It has been proposed that Long Covid is a consequence of either an excessive or inadequate initial immune response. Here, we analyze SARS-CoV-2 humoral and cellular immunity in 86 healthcare workers with laboratory confirmed mild or asymptomatic SARS-CoV-2 infection during the first wave. Symptom questionnaires allow stratification into those with persistent symptoms and those without for comparison. During the period up to 18-weeks post-infection, we observe no difference in antibody responses to spike RBD or nucleoprotein, virus neutralization, or T cell responses. Also, there is no difference in the profile of antibody waning. Analysis at 1-year, after two vaccine doses, comparing those with persistent symptoms to those without, again shows similar SARS-CoV-2 immunity. Thus, quantitative differences in these measured parameters of SARS-CoV-2 adaptive immunity following mild or asymptomatic acute infection are unlikely to have contributed to Long Covid causality. ClinicalTrials.gov (NCT04318314).